Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

legal action

- PMLiVE

J&J’s combo diabetes drug held up by FDA

Regulator wants more dosing data on canaglifozin / metformin product

- PMLiVE

FDA clears J&J’s breakthrough lymphoma therapy

Imbruvica approved to treat mantle cell lymphoma

- PMLiVE

J&J pays $2bn to settle Risperdal mis-selling claims

Concludes nine-year investigation into marketing activities

- PMLiVE

AstraZeneca/J&J form Japanese cancer partnership

Two companies will co-promote Zytiga in prostate cancer

J&J seeks European digital health entrepreneurs

Digital health mentor programme will culminate in €50,000 challenge

- PMLiVE

First mAb biosimilars set for European approval

Celltrion and Hospira's versions of J&J's blockbuster Remicade recommended by CHMP

- PMLiVE

J&J acquires oncology candidate in $1bn Aragon buy

ARN-509 is in phase II development for castration resistant prostate cancer

- PMLiVE

New data backs J&J’s ibrutinib efficacy in B cell cancers

Phase II results showcased at European Hematology Association meeting

- PMLiVE

J&J wins silver for nursing campaign at 2013 North America Effie Awards

‘Healing a profession from the inside out’ designed to acknowledge nursing skills

- PMLiVE

J&J’s Simponi wins FDA approval in ulcerative colitis

Adds to rheumatoid arthritis, psoriatic arthritis and active ankylosing spondylitis indications in the US

- PMLiVE

Johnson & Johnson launches first corporate campaign for decade

Campaign intended to reinforce company values to consumer

Novartis building

Novartis hit by kickback lawsuits in US

Company accused of paying millions of dollars to doctors in exchange for prescribing drugs

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links